BioNTech vs. Moderna: The COVID Vaccine Giants Are Entering a New Era. One Stock Could Have the Edge for 2027

BioNTech and Moderna are transitioning from pandemic-era COVID-19 vaccine dominance to sustainable businesses through oncology and other disease pipelines. BioNTech is favored for 2027 due to its stronger financial position (€16.2 billion cash, zero debt, positive cash flow) and expanding cancer treatment pipeline, while Moderna faces greater financial pressure from declining vaccine revenue despite promising late-stage cancer vaccine results.

11/09/2026, 5:00 AM • The Motley Fool

Bristol Myers Squibb vs. Vertex: Which Pharma Stock Is a Better Buy for 2027?

The article compares Bristol Myers Squibb (BMY) and Vertex Pharmaceuticals (VRTX) as investment options for 2027. BMY trades at a cheaper valuation (9.8x forward P/E) with a 4.06% dividend yield but faces revenue concentration risks and uncertain recovery timeline. VRTX commands a higher valuation (29.8x forward P/E) but demonstrates superior growth prospects, strong margins (85.61%), and successful product launches like Alyftrek. The author recommends Vertex as the better choice, citing its strong execution and growth momentum despite higher valuation multiples.

11/07/2026, 9:37 AM • The Motley Fool

Sickle Cell Disease Clinical Trial Pipeline Gains Momentum: 45+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

Over 45 pharmaceutical companies are advancing 50+ pipeline drugs for sickle cell disease treatment. Key developments include Agios Pharmaceuticals' mitapivat receiving FDA Priority Review, Novo Nordisk's etavopivat meeting Phase III endpoints, and CorrectSequence Therapeutics' CS-206 showing sustained vaso-occlusive crisis-free results. The pipeline features diverse mechanisms including PK activators, gene therapies, and fetal hemoglobin stimulants, with approximately 5+ drugs in late-stage development.

11/03/2026, 1:00 PM • GlobeNewswire

AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy for 2027?

AbbVie and Bristol Myers Squibb represent contrasting investment strategies in pharmaceuticals. AbbVie offers faster growth with strong immunology drugs (Skyrizi, Rinvoq) and expanding pipeline, trading at premium valuations with expected net income growth to $14.6B. Bristol Myers Squibb trades at significantly lower multiples with stable oncology/hematology focus but faces a harder recovery timeline. The article recommends AbbVie for investors seeking immediate growth prospects despite higher valuations.

11/02/2026, 11:00 AM • The Motley Fool

2027 Could Finally Be the Year Cancer Is on the Ropes!

Global cancer research is advancing through AI-supported precision medicine, biomarker-guided treatments, and innovative approaches. Anthropic is supporting pediatric cancer care through the PCX program, while companies like AstraZeneca report survival improvements in gastric cancer with sonesitatug vedotin. Researchers in Japan and South Korea are exploring novel approaches including using cancer cells' own chemistry to produce treatments and reprogramming cancer cells toward normal states.

10/29/2026, 9:10 PM • GlobeNewswire

Bristol Myers’ Growth Drugs Hit $7.7 Billion: Rapid Earnings Reaction

Bristol Myers Squibb's Growth Portfolio of newer drugs surged 12% to $7.7 billion in Q3 2026, driving the company's 7% overall revenue growth to $13.1 billion. While adjusted EPS fell 17% to $1.35, this decline reflects upfront acquisition costs for pipeline drugs rather than core business weakness. The company raised its 2026 revenue guidance to $49.75-$50.25 billion, signaling confidence in its drug portfolio diversification strategy.

10/29/2026, 2:57 PM • The Motley Fool

Global Dermatological Therapeutics Market to Reach USD 97 Billion by 2034 | DelveInsight

The global dermatological therapeutics market is projected to grow from USD 43 billion in 2025 to USD 97 billion by 2034, with a CAGR of approximately 10%. Growth is driven by rising prevalence of chronic skin disorders, adoption of biologics and JAK inhibitors, increased healthcare spending, and growing awareness of skin health. North America leads the market with 46% share, while Asia-Pacific is expected to register the fastest growth.

10/28/2026, 1:00 PM • GlobeNewswire

Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026?

The article compares Amgen and Novo Nordisk as investment options for 2026. Amgen shows stronger revenue growth (9.9%) with a diversified portfolio across oncology and rare diseases, while Novo Nordisk boasts higher profitability (33.1% net margin) but faces pricing pressures and competition in the GLP-1 market. The author recommends Amgen for 2026 due to its consistent revenue growth and scale advantages, despite Novo Nordisk's cheaper valuation multiples.

10/27/2026, 10:50 AM • The Motley Fool

Bristol Myers Squibb’s Cancer Drug Just Doubled Survival Time Without Progression — Here’s Why It Matters

Bristol Myers Squibb announced positive Phase 3 trial results for izalontamab brengitecan (iza-bren), an experimental cancer drug that doubled progression-free survival time (11.1 months vs. 5.7 months) compared to chemotherapy in non-small cell lung cancer patients. However, the stock reaction was muted because the trial was conducted only in China, and FDA approval typically requires multi-region confirmatory data meeting Western standards. The drug represents part of BMY's strategy to transition from legacy medications to a growth portfolio.

10/27/2026, 2:13 AM • The Motley Fool

3 Cheap Dividend Stocks I'd Buy Without Any Hesitation

The article highlights three undervalued dividend stocks trading at attractive valuations: Bristol Myers Squibb (BMY) offers a 4.2% yield with 94 years of dividend payments; Target (TGT) is recovering under new leadership with improving same-store sales and a 3% yield; and PepsiCo (PEP) presents a buying opportunity at 4.3% yield as it adapts to market conditions with accelerating organic revenue growth.

10/26/2026, 3:15 PM • The Motley Fool

Breakfast News: Science Strikes Back at Cancer

Cancer treatment breakthroughs dominate ESMO 2026 conference with multiple drugs showing significant survival gains. U.S. stocks declined amid AI spending concerns and rising oil prices, with the Fed expected to hold rates steady Wednesday. Several Motley Fool-recommended companies report earnings this week including Alphabet, Amazon, and Mastercard. TransDigm's stock decline reflects valuation compression rather than business deterioration.

10/26/2026, 7:30 AM • The Motley Fool

3 High-Yield Stocks to Buy With $1,000 Right Now

The article recommends three high-yield dividend stocks for investors with $1,000: Bristol Myers Squibb (4% yield, 17-year dividend growth streak), Enterprise Products Partners (6.1% yield, 28-year distribution increase streak), and Verizon Communications (6.3% yield, 20-year dividend growth streak). All three stocks offer yields significantly above the S&P 500's ~1% yield and demonstrate strong dividend sustainability through low payout ratios and solid cash flow generation.

10/26/2026, 4:44 AM • The Motley Fool

Should You Buy Bristol Myers Squibb While It Trades Below 10 Times Forward Earnings?

Bristol Myers Squibb trades at a low 9.7x forward P/E ratio due to upcoming patent expirations on blockbuster drugs Opdivo and Eliquis, which will face generic competition. However, the article argues this presents a buying opportunity for long-term investors, as patent losses are normal in pharma, the company has new drugs in development, and it offers an attractive 4.1% dividend yield with a strong history of dividend growth.

10/25/2026, 5:15 PM • The Motley Fool

BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy

BioNTech and Bristol Myers Squibb announced positive Phase 2 data for pumitamig (BNT327/BMS986545), a PD-L1xVEGF-A bispecific immunomodulator, combined with docetaxel in patients with advanced NSCLC who progressed after first-line immunotherapy plus chemotherapy. The trial showed a confirmed objective response rate of 36.7%, median progression-free survival of 6.9 months, and a manageable safety profile, demonstrating potential improvement over standard-of-care docetaxel which typically delivers 3.6-3.9 months PFS.

10/25/2026, 3:30 AM • GlobeNewswire

BioNTech und Bristol Myers Squibb präsentieren ermutigende Daten aus globaler Phase-2-Studie mit Pumitamig bei fortgeschrittenem nicht-kleinzelligem Lungenkrebs nach Progression der Erkrankung unter einer Immuntherapie und Chemotherapie

BioNTech and Bristol Myers Squibb announced positive Phase 2 results from the ROSETTA Lung-107 trial showing Pumitamig (BNT327/BMS986545) in combination with Docetaxel achieved a 36.7% objective response rate and 6.9-month median progression-free survival in patients with metastatic non-small cell lung cancer that progressed after first-line immunotherapy plus chemotherapy. The drug demonstrated a manageable safety profile with consistent activity across PD-L1 expression levels and histological subtypes.

10/25/2026, 3:30 AM • GlobeNewswire